As of Aug 26
| -0.26 / -0.84%|
The 18 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 35.50, with a high estimate of 81.00 and a low estimate of 16.00. The median estimate represents a +15.15% increase from the last price of 30.83.
The current consensus among 21 polled investment analysts is to Hold stock in Valeant Pharmaceuticals. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.